山東藥玻(600529.SH):擬定增募資不超18.66億元 用於一級耐水藥用玻璃瓶項目等
格隆匯9月7日丨山東藥玻(600529.SH)公佈2021年度非公開發行A股股票預案,此次非公開發行A股股票的數量按照此次發行募集資金總額除以發行價格計算得出,且非公開發行A股股票數量不超過此次發行前上市公司總股本594,967,747股的30%,即1.78億股(含本數)。
此次非公開發行股票的定價基準日為此次非公開發行股票發行期的首日,發行價格不低於定價基準日前20個交易日股票交易均價的80%。
此次非公開發行股票募集資金總額為不超過18.66億元(含本數),扣除發行費用後,擬11.96億元用於山東省藥用玻璃股份有限公司一級耐水藥用玻璃瓶項目,擬6.71億元用於年產5.6億隻預灌封注射器擴產改造項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.